Kane Biotech Inc. (KNE.V)
CAD 0.1
(0.0%)
CAD 0.1
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -3.23 Million CAD | -17.82% |
| 2022 | -2.94 Million CAD | 35.41% |
| 2021 | -4.24 Million CAD | -16.5% |
| 2020 | -3.64 Million CAD | -6.46% |
| 2019 | -764.08 Thousand CAD | -10.63% |
| 2018 | -3.09 Million CAD | -18.69% |
| 2017 | -3.24 Million CAD | -3.79% |
| 2016 | -2.37 Million CAD | -49.43% |
| 2015 | -1.56 Million CAD | -14.14% |
| 2014 | -1.47 Million CAD | -9.56% |
| 2013 | -1.35 Million CAD | -5.58% |
| 2012 | -1.42 Million CAD | -9.3% |
| 2011 | -1.19 Million CAD | -37.18% |
| 2010 | -943.83 Thousand CAD | -3.99% |
| 2009 | -837.75 Thousand CAD | 14.39% |
| 2008 | -1.03 Million CAD | -2.74% |
| 2007 | -929.25 Thousand CAD | -11.61% |
| 2006 | -832.6 Thousand CAD | 16.38% |
| 2005 | -969.55 Thousand CAD | -69.75% |
| 2004 | -586.59 Thousand CAD | -51.53% |
| 2003 | -406.86 Thousand CAD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -1.17 Million CAD | -2.34% |
| 2024 Q2 | -1.04 Million CAD | 5.46% |
| 2023 FY | - CAD | -30.57% |
| 2023 Q1 | -1.01 Million CAD | -113.02% |
| 2023 Q2 | -535.72 Thousand CAD | 47.26% |
| 2023 Q4 | -1.09 Million CAD | 1.77% |
| 2023 Q3 | -1.11 Million CAD | -108.38% |
| 2022 Q3 | -756.67 Thousand CAD | -34.71% |
| 2022 Q4 | -476.82 Thousand CAD | 36.98% |
| 2022 Q2 | -561.68 Thousand CAD | 40.87% |
| 2022 Q1 | -950 Thousand CAD | 11.23% |
| 2022 FY | - CAD | 35.41% |
| 2021 Q1 | -904.92 Thousand CAD | -9.04% |
| 2021 Q3 | -1.4 Million CAD | -60.63% |
| 2021 Q4 | -1.07 Million CAD | 23.67% |
| 2021 Q2 | -872.78 Thousand CAD | 3.55% |
| 2021 FY | - CAD | -16.5% |
| 2020 Q2 | -486.48 Thousand CAD | 63.56% |
| 2020 Q4 | -829.9 Thousand CAD | 16.72% |
| 2020 Q3 | -996.52 Thousand CAD | -104.84% |
| 2020 Q1 | -1.33 Million CAD | -21.71% |
| 2020 FY | - CAD | -6.46% |
| 2019 Q2 | -940.98 Thousand CAD | -55.15% |
| 2019 Q3 | -782.37 Thousand CAD | 16.86% |
| 2019 Q4 | -1.09 Million CAD | -40.19% |
| 2019 FY | - CAD | -10.63% |
| 2019 Q1 | -606.5 Thousand CAD | 4.49% |
| 2018 Q4 | -635.02 Thousand CAD | 30.01% |
| 2018 Q1 | -871.61 Thousand CAD | -424.79% |
| 2018 Q2 | -683.44 Thousand CAD | 21.59% |
| 2018 FY | - CAD | -18.69% |
| 2018 Q3 | -907.34 Thousand CAD | -32.76% |
| 2017 Q4 | -166.08 Thousand CAD | 80.55% |
| 2017 FY | - CAD | -3.79% |
| 2017 Q3 | -853.74 Thousand CAD | -18.24% |
| 2017 Q1 | -867.82 Thousand CAD | -87.14% |
| 2017 Q2 | -722.02 Thousand CAD | 16.8% |
| 2016 FY | - CAD | -49.43% |
| 2016 Q4 | -463.72 Thousand CAD | 19.92% |
| 2016 Q2 | -879.79 Thousand CAD | -48.67% |
| 2016 Q3 | -579.08 Thousand CAD | 34.18% |
| 2016 Q1 | -591.77 Thousand CAD | -34.02% |
| 2015 Q2 | -419.37 Thousand CAD | 6.72% |
| 2015 Q4 | -441.54 Thousand CAD | -18.64% |
| 2015 FY | - CAD | -14.14% |
| 2015 Q3 | -372.16 Thousand CAD | 11.26% |
| 2015 Q1 | -449.56 Thousand CAD | -8.38% |
| 2014 Q4 | -414.8 Thousand CAD | -35.33% |
| 2014 Q1 | -275.72 Thousand CAD | -147.2% |
| 2014 Q3 | -306.52 Thousand CAD | 35.75% |
| 2014 Q2 | -477.11 Thousand CAD | -73.04% |
| 2014 FY | - CAD | -9.56% |
| 2013 Q3 | -321.24 Thousand CAD | -1.53% |
| 2013 Q1 | -655.04 Thousand CAD | -62.87% |
| 2013 FY | - CAD | -5.58% |
| 2013 Q4 | -111.53 Thousand CAD | 65.28% |
| 2013 Q2 | -316.41 Thousand CAD | 51.7% |
| 2012 Q1 | -302 Thousand CAD | 0.64% |
| 2012 Q3 | -379.04 Thousand CAD | -11.93% |
| 2012 Q4 | -402.19 Thousand CAD | -6.11% |
| 2012 FY | - CAD | -9.3% |
| 2012 Q2 | -338.65 Thousand CAD | -12.14% |
| 2011 Q1 | -348.23 Thousand CAD | -108.85% |
| 2011 FY | - CAD | -37.18% |
| 2011 Q3 | -334.59 Thousand CAD | -53.15% |
| 2011 Q2 | -218.47 Thousand CAD | 37.26% |
| 2011 Q4 | -303.95 Thousand CAD | 9.16% |
| 2010 Q2 | -177.65 Thousand CAD | 28.34% |
| 2010 Q1 | -247.89 Thousand CAD | -162.5% |
| 2010 Q4 | -166.74 Thousand CAD | 35.28% |
| 2010 Q3 | -257.63 Thousand CAD | -45.02% |
| 2010 FY | - CAD | -3.99% |
| 2009 FY | - CAD | 14.39% |
| 2009 Q1 | -197.22 Thousand CAD | -84.5% |
| 2009 Q4 | -94.43 Thousand CAD | 68.4% |
| 2009 Q2 | -226.84 Thousand CAD | -15.02% |
| 2009 Q3 | -298.81 Thousand CAD | -31.73% |
| 2008 Q1 | -202 Thousand CAD | 6.45% |
| 2008 FY | - CAD | -2.74% |
| 2008 Q4 | -106.89 Thousand CAD | 70.5% |
| 2008 Q3 | -362.41 Thousand CAD | -6.1% |
| 2008 Q2 | -341.58 Thousand CAD | -69.09% |
| 2007 Q1 | -185.28 Thousand CAD | 28.01% |
| 2007 Q2 | -365.23 Thousand CAD | -97.12% |
| 2007 FY | - CAD | -11.61% |
| 2007 Q3 | -162.35 Thousand CAD | 55.55% |
| 2007 Q4 | -215.94 Thousand CAD | -33.01% |
| 2006 Q2 | -234.18 Thousand CAD | -56.27% |
| 2006 FY | - CAD | 16.38% |
| 2006 Q1 | -149.85 Thousand CAD | 44.44% |
| 2006 Q4 | -257.37 Thousand CAD | -33.4% |
| 2006 Q3 | -192.92 Thousand CAD | 17.62% |
| 2005 Q4 | -269.7 Thousand CAD | -5.82% |
| 2005 Q1 | -202.97 Thousand CAD | 13.06% |
| 2005 Q2 | -259.33 Thousand CAD | -27.76% |
| 2005 Q3 | -254.86 Thousand CAD | 1.72% |
| 2005 FY | - CAD | -69.75% |
| 2004 Q4 | -233.47 Thousand CAD | -145.23% |
| 2004 Q3 | -95.2 Thousand CAD | 34.08% |
| 2004 Q2 | -144.42 Thousand CAD | -40.24% |
| 2004 FY | - CAD | -51.53% |
| 2004 Q1 | -102.98 Thousand CAD | -128.81% |
| 2003 Q2 | -24.18 Thousand CAD | 0.0% |
| 2003 Q3 | -170.65 Thousand CAD | -605.63% |
| 2003 FY | - CAD | 0.0% |
| 2003 Q4 | -45 Thousand CAD | 73.63% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Arch Biopartners Inc. | -430.71 Thousand CAD | -650.934% |
| Covalon Technologies Ltd. | -3.49 Million CAD | 7.367% |
| Hemostemix Inc. | -1.94 Million CAD | -66.228% |
| Universal Ibogaine Inc. | -4.6 Million CAD | 29.799% |
| MedMira Inc. | -1.57 Million CAD | -105.068% |
| Marvel Biosciences Corp. | -2.25 Million CAD | -43.623% |
| NervGen Pharma Corp. | -17.72 Million CAD | 81.749% |
| XORTX Therapeutics Inc. | -6.46 Million CAD | 49.998% |